EOLS Evolus Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EOLS

Price (delayed)

$6.595

Market cap

$434.31M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$549.42M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only ...

Highlights
The company's EPS rose by 24% YoY and by 16% QoQ
Evolus's net income has increased by 23% YoY and by 16% QoQ
The quick ratio has declined by 27% year-on-year but it has grown by 4.2% since the previous quarter
The debt rose by 27% year-on-year and by 6% since the previous quarter
Evolus's equity has decreased by 25% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.evolus.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of EOLS

EOLS stock price

How has the Evolus stock price performed over time
Intraday
9.37%
1 week
0.38%
1 month
18.19%
1 year
-32.7%
YTD
-0.83%
QTD
60.46%

Financial performance

How have Evolus's revenue and profit performed over time
Revenue
$301.79M
Gross profit
$199.35M
Operating income
-$24.34M
Net income
-$43.42M
Gross margin
66.1%
Net margin
-14.4%
The company's operating margin rose by 45% YoY and by 26% QoQ
The operating income is up by 40% year-on-year and by 25% since the previous quarter
The net margin rose by 29% year-on-year and by 17% since the previous quarter
Evolus's net income has increased by 23% YoY and by 16% QoQ

Price vs fundamentals

How does EOLS's price correlate with its fundamentals

Growth

What is Evolus's growth rate over time

Valuation

What is Evolus stock price valuation
P/E
N/A
P/B
N/A
P/S
1.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.82
The company's EPS rose by 24% YoY and by 16% QoQ
Evolus's equity has decreased by 25% QoQ
The P/S is 61% less than the 5-year quarterly average of 3.3 and 13% less than the last 4 quarters average of 1.5
Evolus's revenue has increased by 10% YoY

Efficiency

How efficient is Evolus business performance
The ROIC has soared by 52% YoY and by 30% from the previous quarter
The company's return on sales rose by 43% YoY and by 27% QoQ
Evolus's ROA has increased by 21% YoY and by 17% from the previous quarter

Dividends

What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EOLS.

Financial health

How did Evolus financials performed over time
The total assets is 12% less than the total liabilities
The quick ratio has declined by 27% year-on-year but it has grown by 4.2% since the previous quarter
The company's current ratio fell by 13% YoY but it rose by 7% QoQ
Evolus's debt to equity has surged by 71% YoY and by 15% QoQ
The debt rose by 27% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.